呼吸体外膜肺氧合生存预测（RESP）评分对新型冠状病毒肺炎急性呼吸窘迫综合征（COVID-19 ARDS）和非新型冠状病毒肺炎急性呼吸窘迫综合征（非COVID-19 ARDS）患者生存情况的预测能力：一项单中心回顾性研究。
Ability of the respiratory ECMO survival prediction (RESP) score to predict survival for patients with COVID-19 ARDS and non-COVID-19 ARDS: a single-center retrospective study.
作者信息
Pratt Elias H, Morrison Samantha, Green Cynthia L, Rackley Craig R
机构信息
Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine, Durham, NC, USA.
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
出版信息
J Intensive Care. 2023 Sep 1;11(1):37. doi: 10.1186/s40560-023-00686-z.
The respiratory ECMO survival prediction (RESP) score is used to predict survival for patients managed with extracorporeal membrane oxygenation (ECMO), but its performance in patients with Coronavirus Disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is unclear. We evaluated the ability of the RESP score to predict survival for patients with both non-COVID 19 ARDS and COVID-19 ARDS managed with ECMO at our institution. Receiver operating characteristic area under the curve (AUC) analysis found the RESP score reasonably predicted survival in patients with non-COVID-19 ARDS (AUC 0.76, 95% CI 0.68-0.83), but not patients with COVID-19 ARDS (AUC 0.54, 95% CI 0.41-0.66).
呼吸体外膜肺氧合生存预测（RESP）评分用于预测接受体外膜肺氧合（ECMO）治疗患者的生存情况，但其在2019冠状病毒病（COVID-19）急性呼吸窘迫综合征（ARDS）患者中的表现尚不清楚。我们评估了RESP评分对我院接受ECMO治疗的非COVID-19 ARDS和COVID-19 ARDS患者生存情况的预测能力。受试者工作特征曲线下面积（AUC）分析发现，RESP评分能合理预测非COVID-19 ARDS患者的生存情况（AUC 0.76，95%CI 0.68-0.83），但不能预测COVID-19 ARDS患者的生存情况（AUC 0.54，95%CI 0.41-0.66）。
Zotero 插件